RXRX: Recursion Pharmaceuticals, Inc. Stock

by  •  • Comments Off on RXRX: Recursion Pharmaceuticals, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 2,089.93
Enterprise Value ($M) 1,496.38
Book Value ($M) 1,034.78
Book Value / Share 2.62
Price / Book 2.02
NCAV ($M) 300.45
NCAV / Share 0.76
Price / NCAV 6.96

Profitability (mra)
Return on Invested Capital (ROIC) -0.41
Return on Assets (ROA) -0.83
Return on Equity (ROE) -1.16

Liquidity (mrq)
Quick Ratio 3.81
Current Ratio 3.81

Balance Sheet (mrq) ($M)
Current Assets 714.27
Assets 1,448.60
Liabilities 413.82
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 58.84
Operating Income -479.00
Net Income -463.66

Cash Flow Statement (mra) ($M)
Cash From Operations -359.17
Cash from Investing 260.06
Cash from Financing 304.12

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Ra Capital Management, L.p. 2.00 -49.79
02-14 13G/A ARK Investment Management LLC 8.47 40.17
02-05 13G/A BlackRock, Inc. 6.10 12.99
11-12 13G/A Fmr Llc 3.04 -23.25
11-12 13G/A Vanguard Group Inc 8.82 0.00
11-04 13G/A Kinnevik AB (publ) 4.30 14.42
10-18 13G/A State Street Corp 4.70 5.91

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PUR
2024-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION R
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPOR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-01 3,419,344 15,709,157 21.77
2025-03-31 3,883,062 15,901,161 24.42
2025-03-28 3,510,035 13,908,612 25.24
2025-03-27 3,559,876 13,242,817 26.88

(click for more detail)

Similar Companies
RPRX – Royalty Pharma plc RPTX – Repare Therapeutics Inc.
RVMD – Revolution Medicines, Inc. SANA – Sana Biotechnology, Inc.
SCPH – scPharmaceuticals Inc.


Financial data and stock pages provided by
Fintel.io